Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy

Overview of attention for article published in Journal of Neurology, August 2013

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#34 of 4,958)
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

news: 15 news outlets
policy: 1 policy source

twitter: 1 X user
patent: 12 patents

Readers on

mendeley: 228 Mendeley

Summary News Policy documents X Patents

So far, Altmetric has seen 17 news stories from 15 outlets.

Amyloid Publishes Long-Term Data Analysis from Pfizer Suggesting Tafamidis Delays Progression of TTR-FAP, a Rare Disease

Stockhouse, 31 Aug 2017

Analysis Provides Longest Evaluation of Any Medication for Hereditary Transthyretin Amyloid Polyneuropathy (TTR-FAP), a…

Amyloid Publishes Long-Term Data Analysis from Pfizer Suggesting Tafamidis Delays Progression of TTR-FAP, a Rare Disease

Wall Street Online Denmark, 31 Aug 2017

Pfizer Inc. (NYSE:PFE) announced the publication of a new interim analysis of long-term data from four studies indicating that…

Amyloid Publishes Long-Term Data Analysis from Pfizer Suggesting Tafamidis Delays Progression of TTR-FAP, a Rare Disease

Benzinga, 31 Aug 2017

Analysis Provides Longest Evaluation of Any Medication for Hereditary Transthyretin Amyloid Polyneuropathy (TTR-FAP), a…

Amyloid Publishes Long-Term Data Analysis from Pfizer Suggesting Tafamidis Delays Progression of TTR-FAP, a Rare Disease

Ariva, 31 Aug 2017

NEW YORK --(BUSINESS WIRE)-- Pfizer Inc. (NYSE:PFE) announced the publication of a new interim analysis of long-term data from…

Amyloid Publishes Long-Term Data Analysis from Pfizer Suggesting Tafamidis Delays Progression of TTR-FAP, a Rare Disease

Business Wire, 31 Aug 2017

NEW YORK--( BUSINESS WIRE )--Pfizer Inc. (NYSE:PFE) announced the publication of a new interim analysis of long-term data from…

Amyloid Publishes Long-Term Data Analysis from Pfizer Suggesting Tafamidis Delays Progression of TTR-FAP, a Rare Disease

NASDAQ, 31 Aug 2017

Analysis Provides Longest Evaluation of Any Medication for Hereditary Transthyretin Amyloid Polyneuropathy (TTR-FAP), a…

Pfizer Announces Publication of New Analysis Showing Long-Term Therapy with VYNDAQEL (tafamidis) Slowed Progression of Rare Neurodegenerative Disease

TMCnet.com, 08 Aug 2016

] Pfizer Inc. (NYSE:PFE) announced the publication of a new post-hoc analysis of data from three studies of VYNDAQEL in…

Pfizer Announces Publication of New Analysis Showing Long-Term Therapy with VYNDAQEL (tafamidis) Slowed Progression of Rare Neurodegenerative Disease

BioMed Reports, 08 Aug 2016

Aug. 8, 2016 12:00 UTC NEW YORK--( BUSINESS WIRE )-- Pfizer Inc. (NYSE:PFE) announced the publication of a new post-hoc…

Pfizer Announces Publication of New Analysis Showing Long-Term Therapy with VYNDAQEL (tafamidis) Slowed Progression of Rare Neurodegenerative Disease

News Channel, 08 Aug 2016

NEW YORK --(BUSINESS WIRE) Pfizer Inc. (NYSE:PFE) announced the publication of a new post-hoc analysis of data from three…

Pfizer Announces Publication of New Analysis Showing Long-Term Therapy with VYNDAQEL (tafamidis) Slowed Progression of Rare Neurodegenerative Disease

News Channel 6, 08 Aug 2016

NEW YORK --(BUSINESS WIRE) Pfizer Inc. (NYSE:PFE) announced the publication of a new post-hoc analysis of data from three…

Pfizer Announces Publication of New Analysis Showing Long-Term Therapy with VYNDAQEL (tafamidis) Slowed Progression of Rare Neurodegenerative Disease

Wall Street Online Germany, 08 Aug 2016

Pfizer Inc. (NYSE:PFE) announced the publication of a new post-hoc analysis of data from three studies of VYNDAQEL in patients…

Pfizer Announces Publication of New Analysis Showing Long-Term Therapy with VYNDAQEL (tafamidis) Slowed Progression of Rare Neurodegenerative Disease

Noodls, 08 Aug 2016

Pfizer Inc. (via noodls) / NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced the publication of a new post-hoc…

Pfizer Announces Publication of New Analysis Showing Long-Term Therapy with VYNDAQEL (tafamidis) Slowed Progression of Rare Neurodegenerative Disease - Press Release

Digital Journal, 08 Aug 2016

NEW YORK--(Business Wire)--Pfizer Inc. (NYSE:PFE) announced the publication of a new post-hoc analysis of data from three…

Pfizer Announces Publication of New Analysis Showing Long-Term Therapy with VYNDAQEL (tafamidis) Slowed Progression of Rare Neurodegenerative Disease

Business Wire, 08 Aug 2016

NEW YORK--( BUSINESS WIRE )--Pfizer Inc. (NYSE:PFE) announced the publication of a new post-hoc analysis of data from three…

Pfizer Announces Publication of New Analysis Showing Long-Term Therapy with VYNDAQEL (tafamidis) Slowed Progression of Rare Neurodegenerative Disease

Stock Nod: Quotes, 08 Aug 2016

. (NYSE:PFE) announced the publication of a new post-hoc analysis of data from three studies of VYNDAQEL in patients with mild…

Pfizer Announces Publication of New Analysis Showing Long-Term Therapy with VYNDAQEL (tafamidis) Slowed Progression of Rare Neurodegenerative Disease

Minyanville: Finance , 08 Aug 2016

Pfizer Inc. (NYSE:PFE) announced the publication of a new post-hoc analysis of data from three studies of VYNDAQEL in patients…

Pfizer Announces Publication of New Analysis Showing Long-Term Therapy with VYNDAQEL (tafamidis) Slowed Progression of Rare Neurodegenerative Disease

NASDAQ, 08 Aug 2016

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE:PFE) announced the publication of a new post-hoc analysis of data from three…